EchoIQ Ltd
ASX:EIQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
EchoIQ Ltd
ASX:EIQ
|
AU |
|
Distribusi Voucher Nusantara Tbk PT
IDX:DIVA
|
ID |
|
Natural Resource Partners LP
NYSE:NRP
|
US |
|
Spring Valley Acquisition Corp II
NASDAQ:SVII
|
US |
|
Shanghai Zhangjiang Hi-Tech Park Development Co Ltd
SSE:600895
|
CN |
|
Connected IO Ltd
ASX:CIO
|
US |
|
Fukuoka Financial Group Inc
OTC:FKKFY
|
JP |
|
Luoniushan Co Ltd
SZSE:000735
|
CN |
|
Jiangsu Flag Chemical Industry Co Ltd
SZSE:300575
|
CN |
|
C
|
Chongqing Changjiang River Moulding Material Group Co Ltd
SZSE:001296
|
CN |
|
T
|
Top Glove Corporation Bhd
KLSE:TOPGLOV
|
MY |
|
F
|
Farsoon Technologies Co Ltd
SSE:688433
|
CN |
|
Brilliance Technology Co Ltd
SZSE:300542
|
CN |
|
Daibiru Corp
TSE:8806
|
JP |
|
Hulic Co Ltd
TSE:3003
|
JP |
EchoIQ Ltd
EchoIQ Ltd. engages in the development, marketing and commercialization of software, products and services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2010-12-17. The firm is engaged in the product development, marketing and commercialization of software products and services. The company provides cardiac diagnostics technology. ECHOiQ’s technology uses artificial intelligence (ai) assisted diagnostics to deliver real-world health solutions. Its screening program uses an AI backed system and access to cardiac big data that identifies patients at risk from aortic stenosis and other forms of structural heart disease. Its technology addresses aortic stenosis, heart failure, and mitral and tricuspid regurgitation. The firm also offers Prometheus that help health funds and insurers understand their providers. The company identifies providers showing signs or early indicators of unusual behaviors that might be related to fraud, claiming errors, or other patterns worthy of further investigation.
EchoIQ Ltd. engages in the development, marketing and commercialization of software, products and services. The company is headquartered in Sydney, New South Wales. The company went IPO on 2010-12-17. The firm is engaged in the product development, marketing and commercialization of software products and services. The company provides cardiac diagnostics technology. ECHOiQ’s technology uses artificial intelligence (ai) assisted diagnostics to deliver real-world health solutions. Its screening program uses an AI backed system and access to cardiac big data that identifies patients at risk from aortic stenosis and other forms of structural heart disease. Its technology addresses aortic stenosis, heart failure, and mitral and tricuspid regurgitation. The firm also offers Prometheus that help health funds and insurers understand their providers. The company identifies providers showing signs or early indicators of unusual behaviors that might be related to fraud, claiming errors, or other patterns worthy of further investigation.
